
|Articles|April 15, 2004
FDA ready to set standards for contrast sensitivity testing
The FDA soon will approve standards for contrast sensitivity testing in clinical trials. The approval is a step that will not only make the administration of this test easier for ophthalmologists but its comparison with clinical trial data and other testing centers simpler and more valuable as well.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
4
What changed in glaucoma care in 2025: Surgeon perspective
5












































